Skip to content
The Nexus
DossierENTITY

primary membranous nephropathy

Coverage of primary membranous nephropathy in the Nexus archive.

Earliest in view: Jun 5 · 16:55 UTCMost recent: Jun 5 · 16:55 UTC
Co-mentioned in this coverage
MedPage Todayorganization1obinutuzumabtopic1Gazyvatopic1tacrolimustopic1MAJESTY trialtopic1
Recent coverage
  • HEALTHJun 5 · 16:55 UTCMEDPAGE TODAY
    B-Cell Depleter Nabs Phase III Win in Autoimmune Kidney Disease

    The B-cell depleting agent obinutuzumab (Gazyva) was superior to the immunosuppressant tacrolimus in inducing remissions in primary membranous nephropathy, according to the global phase III MAJESTY trial. By week 104, 37% of patients achieved remission.

primary membranous nephropathy · Dossier · The Nexus